Palmar plantar erythrodysesthesia epidemiology and demographics
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics |
|
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Palmar plantar erythrodysesthesia epidemiology and demographics in the news |
|
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Palmar Plantar Erythrodysesthesia or Hand-Foot syndrome is a skin-related reaction involving the palms an soles. It commonly occurs due to a reaction to different kinds of chemotherapeutic agent used to treat cancer. The first s. PPE may be classified into grade1, grade 2, grade 3, or grade 4 depending on toxicity rating. The pathophysiologic mechanism of Palmar Plantar Erythrodysesthesia is under active investigation and different mechanisms have been postulated. Histologic biopsy is consistent with toxic reaction[1]. After extensive studies, it has been determined that Pegylated Liposomal doxorubicin deposits into the eccrine glands which is concentrated in the palms and soles which then causes a drug reaction and development of PPE.[2] Several Different types of Chemotherapeutic agents have been associated with the development of Palmar Plantar Erythrodysesthesia. PPE must be differentiated from Acute Graft Versus Host Response, Tinea manuum and Hand-Foot reaction due to tyrosine kinase inhibitor.
Epidemiology and demographics
PPE occurs in 6-42% of patients receiving chemotherapy.
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A; et al. (2014). "Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy". Skin Pharmacol Physiol. 27 (2): 66–70. doi:10.1159/000351801. PMID 23969763.